4022-81-5

Usage

Uses

1. Used in Pharmaceutical Applications:
1-(4-CHLOROPHENYL)BIGUANIDE HYDROCHLORIDE is used as an inhibitor for dihydrofolate reductase (DHFR) due to its ability to significantly inhibit the enzyme. This inhibition can potentially lead to the disruption of cellular metabolism and DNA synthesis, making it a promising candidate for the development of therapeutic agents targeting various diseases, particularly those involving rapid cell proliferation.
2. Used in Anticancer Research:
In the field of oncology, 1-(4-CHLOROPHENYL)BIGUANIDE HYDROCHLORIDE is used as a research tool to study the role of dihydrofolate reductase (DHFR) in cancer cell growth and proliferation. By understanding the compound's interaction with DHFR, researchers can gain insights into the development of novel anticancer drugs that target this enzyme, potentially leading to more effective treatments for various types of cancer.
3. Used in Drug Design and Development:
1-(4-CHLOROPHENYL)BIGUANIDE HYDROCHLORIDE serves as a valuable starting point for the design and development of new drugs targeting dihydrofolate reductase (DHFR). Its structure can be modified and optimized to improve its potency, selectivity, and pharmacokinetic properties, ultimately leading to the creation of more effective therapeutic agents for the treatment of diseases associated with dysregulated DHFR activity.
4. Used in Biochemical and Molecular Biology Research:
In addition to its pharmaceutical applications, 1-(4-CHLOROPHENYL)BIGUANIDE HYDROCHLORIDE is also used as a research tool in biochemical and molecular biology studies. It can be employed to investigate the structure, function, and regulation of dihydrofolate reductase (DHFR) and its role in various biological processes, including cell growth, DNA replication, and gene expression.

InChI:InChI=1/C8H10ClN5/c9-5-1-3-6(4-2-5)13-8(12)14-7(10)11/h1-4H,(H6,10,11,12,13,14)/p+2

Upstream product

• 106-47-8 4-chloro-aniline 
• 127099-85-8 N-Cyanoguanidine 

Downstream Products

• 672-93-5 6-ethyl-N-(4-chloro-phenyl)-[1,3,5]triazine-2,4-diamine 
• 50427-07-1 1-[4-amino-6-(4-chloro-anilino)-[1,3,5]triazin-2-yl]-propan-2-one 
• 5429-13-0 N-(4-chloro-phenyl)-N'-(4-methyl-6-oxo-1,6-dihydro-pyrimidin-2-yl)-guanidine 
• 131762-02-2 1-(4-chloro-phenyl)-6-methyl-6-propyl-1,6-dihydro-[1,3,5]triazine-2,4-diyldiamine; hydrochloride 
• 30805-25-5 1-(4-chloro-phenyl)-6-isopropyl-1,6-dihydro-[1,3,5]triazine-2,4-diyldiamine 
• 516-21-2 cycloguanil 
• 104509-37-7 1-(4-chloro-phenyl)-6-ethyl-6-methyl-1,6-dihydro-[1,3,5]triazine-2,4-diamine 
• 16018-51-2 4,6-Dimethyl-2-(p-chlorphenyl)-guanidinopyrimidin 
• 86176-96-7 N-(4-Chloro-phenyl)-N'-(4-hydroxy-6-trifluoromethyl-pyrimidin-2-yl)-guanidine 
• 96730-35-7 1-(4'-chlorophenyl)-2-phenyl-4,6-diamino-1,2-dihydro-1,3,5-triazine hydrochloride 
• 152-53-4 cycloguanil hydrochloride 
• 5405-65-2 N₂-(4-chloro-phenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine 
• 645-18-1 N-(4-chloro-phenyl)-6-methyl-[1,3,5]triazine-2,4-diamine 
• 30355-61-4 6-(chloromethyl)-N²-(4-chlorophenyl)-1,3,5-triazine-2,4-diamine 

Relevant academic research and scientific papers

Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT-β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2

By screening a focused library of kinase inhibitor analogues in a phenotypic co-culture assay for angiogenesis inhibition, we identified an aminotriazine that acts as a cytostatic nanomolar inhibitor. However, this aminotriazine was found to be completely inactive in a whole-kinome profiling assay. To decipher its mechanism of action, we used the online target prediction tool PPB2 (http://ppb2.gdb.tools), which suggested lysophosphatidic acid acyltransferase β (LPAAT-β) as a possible target for this aminotriazine as well as several analogues identified by structure–activity relationship profiling. LPAAT-β inhibition (IC50 ≈15 nm) was confirmed in a biochemical assay and by its effects on cell proliferation in comparison with a known LPAAT-β inhibitor. These experiments illustrate the value of target-prediction tools to guide target identification for phenotypic screening hits and significantly expand the rather limited pharmacology of LPAAT-β inhibitors.

BIGUANIDE COMPOUND AND USE THEREOF

The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.

Incorporation of a Biguanide Scaffold Enhances Drug Uptake by Organic Cation Transporters 1 and 2

Membrane transporters play a significant role in the transport of many endogenous and exogenous compounds. The knowledge of transporter substrate requirements has allowed further development of drugs that utilize them to ensure tissue permeation. In this

Synthesis and antiviral activity of benzimidazolyl-and triazolyl-1,3,5- triazines

A novel series of 1,3,5-triazine analogs was successfully synthesized through conjugation with benzimidazole or 1,2,4-triazole derivatives via a methylenethio linker. The new analogs were in vitro evaluated against HSV-1 in Vero cells; among these analogs, two compounds exhibited good effect in inhibiting HSV-1 replication (for compound 5p: EC50 = 3.5 μg/ml, SI = 358; for compound 5r: EC50 = 5.0 μg/ml, SI = 300) in comparison to acyclovir. Springer Science+Business Media, LLC 2011.

High yielding microwave-assisted synthesis of 2-(arylmethyl)amino-4-arylamino-6-alkyl-1,3,5-triazines

An efficient and practical procedure was developed to prepare novel 2-(arylmethyl)amino-4-arylamino-6-alkyl-1,3,5-triazines, starting from dicyandiamide and the corresponding arylamines under microwave irradiation and its scope is demonstrated with a number of examples. The valuable feature of this procedure included the short reaction times, high yields, and easy operation.

Synthesis and in vitro evaluation of 2,4-diamino-1,3,5-triazine derivatives as neuronal voltage-gated sodium channel blockers

Neuronal sodium channels blockers interfere with ion flux and have been used for managing neuropathic pain, epilepsy, and cerebral ischemic disorders. In the current study, four groups of 2,4-diamino-1,3,5-triazine derivatives were synthesized and investigated for their neuronal sodium channels binding activity. 5-Aryl-1,3,5-triazaspiro[5.5]undeca-1,3-diene-2,4-diamines (4a-4j) were found to have the best neuronal sodium binding activity among the four groups of triazines evaluated. Derivatives 4a-4j blocked the sodium channels with IC50 values ranged from 4.0 to 14.7 μM. The result from this study showed that analogues of 2,4-diamino-1,3,5-triazines could be used as leads for the discovery of neuronal sodium channels blockers for managing central nervous system related disorders.